Paul Klekotka
- Immunology top 1%
- Psoriasis: Treatment and Pathogenesis 17
- Dermatology top 0.5%
- Dermatology and Skin Diseases 14
- Immunology and Allergy top 5%
- Hematology top 5%
- Autoimmune and Inflammatory Disorders Research 4
- Rheumatology top 5%
-
- Asthma and respiratory diseases 10
-
- SARS-CoV-2 and COVID-19 Research 8
- COVID-19 Clinical Research Studies 6
-
- Inflammatory Bowel Disease 6
-
- Microscopic Colitis 6
- Co-authors
- Chris B. RussellJames G. KruegerAjay NirulaGregory KricorianGreg KricorianKim PappRoland MartinꝉJennifer E. Towne
- Journals
- Journal of the American Chemical Society (1 paper)Journal of Biological Chemistry (2 papers)Nature Communications (1 paper)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Paul Klekotka
41 papers receiving 3.1k citations
Hit Papers
Peers
Comparison fields: 5 of 118
- Immunology 2.4k
- Dermatology 939
- Immunology and Allergy 170
- Hematology 258
- Rheumatology 311
Countries citing papers authored by Paul Klekotka
This map shows the geographic impact of Paul Klekotka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Klekotka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Klekotka more than expected).
Fields of papers citing papers by Paul Klekotka
This network shows the impact of papers produced by Paul Klekotka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Klekotka. The network helps show where Paul Klekotka may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Paul Klekotka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 2 | |
| 6 | 2024 | 1 | |
| 7 | 2022 | 5 | |
| 8 | Bamlanivimab+etesevimab for treatment of COVID-19 in high-risk ambulatory patients | 2021 | 6 |
| 9 | Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting | 2021 | 4 |
| 10 | 2019 | 57 | |
| 11 | 2019 | 179 | |
| 12 | 2017 | 223 | |
| 13 | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Diseasebreakdown → | 2016 | 289 |
| 14 | 2015 | 58 | |
| 15 | 2014 | 36 | |
| 16 | 2012 | 99 | |
| 17 | 2011 | 88 | |
| 18 | 2009 | 34 | |
| 19 | 1995 | 2 | |
| 20 | 1994 | 56 |
About Paul Klekotka
Paul Klekotka is a scholar working on Dermatology, Immunology and Complementary and Manual Therapy, having authored 45 papers that have together received 3.2k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (17 papers), Dermatology and Skin Diseases (14 papers), Asthma and respiratory diseases (10 papers), SARS-CoV-2 and COVID-19 Research (8 papers), COVID-19 Clinical Research Studies (6 papers), Inflammatory Bowel Disease (6 papers), Microscopic Colitis (6 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). The work is most often cited by research in Immunology (2.4k citations), Dermatology (939 citations) and Immunology and Allergy (170 citations). Paul Klekotka has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Chris B. Russell, James G. Krueger, Ajay Nirula, Gregory Kricorian, Greg Kricorian, Kim Papp, Roland Martinꝉ, Jennifer E. Towne, Brian G. Feagan and Jóhann E. Guðjónsson. Their work appears in journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.